DARE logo

Dare Bioscience, Inc.

DARE
Healthcare|Biotechnology|US
$0.64
+0.01 (+2.40%)
DCF Value
$0.18
Cash / Share
$0.85
Next Earnings Report
Nov 12, 2026
EPS est. -$0.13 · Revenue est. $2.0M
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Sep 4, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (1)

Dec 2100
Est. completion
Rare Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT01793168n=20,000

Recent Press Releases

Daré Bioscience to Present at Stifel's 2026 Healthcare Conference
Nov 4, 2026 · GlobeNewsWire
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Oct 30, 2026 · GlobeNewsWire
Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion
Oct 28, 2026 · GlobeNewsWire
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Oct 26, 2026 · GlobeNewsWire
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Oct 19, 2026 · GlobeNewsWire
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
Oct 13, 2026 · GlobeNewsWire
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Sep 28, 2026 · GlobeNewsWire
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Sep 14, 2026 · GlobeNewsWire
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
Sep 11, 2026 · GlobeNewsWire
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
Aug 31, 2026 · GlobeNewsWire

SEC Filings (88)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Oct 6, 2026DEF 14AProxy / shareholder voteDocumentIndex
Oct 2, 20268-KMaterial eventDocumentIndex
Oct 1, 20268-KMaterial eventDocumentIndex
Sep 23, 2026PRE 14AProxy / shareholder voteDocumentIndex
Sep 11, 20268-KMaterial eventDocumentIndex
Sep 9, 20268-KMaterial eventDocumentIndex
Sep 4, 2026424B3Offering prospectusDocumentIndex
Sep 3, 2026EFFECTDocumentIndex
Aug 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 26, 2026S-1IPO / offering registrationDocumentIndex
Aug 24, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 20, 2026DDocumentIndex
Aug 19, 2026253G2DocumentIndex
Aug 17, 20268-KMaterial eventDocumentIndex
Aug 17, 2026424B5Offering prospectusDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Jul 24, 20268-KMaterial eventDocumentIndex
Jul 17, 2026253G2DocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jul 13, 20268-KMaterial eventDocumentIndex
Jun 23, 2026S-8Employee stock planDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
Jun 1, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jun 1, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 18, 20268-KMaterial eventDocumentIndex
May 15, 2026253G2DocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 20, 20268-KMaterial eventDocumentIndex
Apr 17, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 13, 20268-KMaterial eventDocumentIndex